Uflex Ltd Q1 FY27 Earnings Analysis

- **Packaging business growth:** Expected to perform better in FY27 than FY26 due to improved utilization of recently commissioned capacities, product mix optimization, and new capacities coming online. - **Aseptic packaging volumes:** Anticipated to increase from ~8 billion packs in FY26 to about 10.5 billion packs in FY27, including ramp-up of new capacity in Egypt. - **Packaging films volumes:** Sequential recovery noted; however, FY26 volume declined 1%. Expect continued demand improvement but moderated by macroeconomic factors. - **Regional growth:** Americas showed strong volume growth (23% Q-o-Q and 18% YoY) with improvements expected to continue. - **Long-term prospects:** Supported by rising income levels, shifting consumer habits, accelerating urbanization, driving higher FMCG consumption and thus packaging demand. - **EBITDA contribution:** Packaging Solutions (including aseptic) expected to increase its share from current ~40% to higher, indicating margin improvement. - **Capex-driven growth:** New projects commissioning leading to increased revenues and volumes, e.g., BOPP line in Dharwad, aseptic facility in Egypt.

- Packaging Solutions business EBITDA contribution is expected to increase with new capacities commissioned, including aseptic packaging, WPP, and recycling segments (Page 19). - The company projects aseptic packaging volumes to grow from 8 billion packs in FY26 to around 10.5 billion packs in FY27, factoring ramp-up in Egypt facility (Page 18). - EBITDA margin improved by 70 bps YoY to 12.8% in FY26, with further margin expansion anticipated in Packaging Solutions due to higher value-added products (Page 10, 17). - New projects in Egypt (aseptic packaging), Mexico (WPP bags), recycling, and Dharwad BOPP lines are expected to contribute significant EBITDA from FY27 onwards (Page 9, 15). - Operating leverage from recently commissioned facilities, product mix optimization, and higher utilization are key drivers for improved profits and EPS in FY27 and beyond (Page 6, 18). - Management remains optimistic about long-term growth, facilitated by rising income, urbanization, and consumption trends in key markets (Page 6).

- Current capex focuses on four key projects: - Aseptic packaging facility in Egypt (12 billion capacity, commissioning in H1 FY27) - WPP bag manufacturing unit in Mexico, targeting North America pet food market - PET recycling facility in India (commissioned in April FY26) - New BOPP packaging film manufacturing line in Dharwad, India (54,000 MTPA capacity, commissioning in FY27-28) - Remaining capex to be capitalized in FY27 is around Rs. 1,900 - 2,000 crore, including Rs. 972 crore for aseptic facility and minor amounts for recycling. - Post these projects, focus will be on increasing asset utilization and optimizing capex to ensure EBITDA growth. - Open to new value-accretive capex globally with high margin potential and right product mix. - Current phase is near the peak debt and commissioning; next phase expected to be sweating the assets with improved utilization.

- No specific refinancing initiatives have been undertaken yet; management considers it premature to discuss refinancing options at this stage. - The company is open to refinancing but is currently focusing on sourcing funds at more attractive or cheaper costs. - Recent capex has been funded through a mix of debt and internal accruals; peak debt may have been reached with near-commissioned projects. - The company expects EBITDA growth from commissioned projects to improve leverage ratios despite elevated absolute debt levels. - Future capex will be evaluated based on value accretiveness and margin expansion opportunities; no concrete plans for new fundraises via equity or debt were mentioned. - Overall blended cost of funds currently stands at approximately 9%.

The transcript provided does not mention any specific details about the current or expected order book or pending orders for UFlex Limited. The discussion primarily focuses on: - Capacity utilization and expansion plans (e.g., aseptic packaging capacity in India and Egypt). - Capex projects and their commissioning timelines. - EBITDA margins and financial performance trends. - Market dynamics in various product segments and regions. - Cost of debt and leverage ratios. - Growth prospects and strategy across packaging segments. No direct reference or quantitative information about order book status or pending orders is provided in the earnings call transcript.